(Q36106470)

English

Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15852457%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference

Europe PubMed Central

Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15852457%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15852457%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

author name string

Xiaoning Zhao

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15852457%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Riccardo Perfetti

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15852457%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

publication date

1 July 2005

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15852457%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Diabetes - Metabolism: Research and Reviews

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15852457%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15852457%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15852457%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

313-331

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15852457%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Differential Processing of Proglucagon by the Subtilisin-like Prohormone Convertases PC2 and PC3 to Generate either Glucagon or Glucagon-like Peptide

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

21 January 2018

GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

21 January 2018

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

21 January 2018

Are diprotin A (Ile-Pro-Ile) and diprotin B (Val-Pro-Leu) inhibitors or substrates of dipeptidyl peptidase IV?

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

21 January 2018

Hamster preproglucagon contains the sequence of glucagon and two related peptides

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-Like Peptides GLP-1 and GLP-2, Predicted Products of the Glucagon Gene, Are Secreted Separately from Pig Small Intestine but Not Pancreas*

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Minireview: the glucagon-like peptides

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of glucose and glucagon-like peptide-1 stimulation on insulin release in the perfused pancreas in a non-insulin-dependent diabetes mellitus animal model.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide 1 improved glycemic control in type 1 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Cultured pancreatic ductal cells undergo cell cycle re-distribution and beta-cell-like differentiation in response to glucagon-like peptide-1.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

GLP-1 stimulates glucose-derived de novo fatty acid synthesis and chain elongation during cell differentiation and insulin release

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

cAMP Dose-dependently prevents palmitate-induced apoptosis by both protein kinase A- and cAMP-guanine nucleotide exchange factor-dependent pathways in beta-cells

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-Like Peptide-1 Synthetic Analogs: New Therapeutic Agents for Use in the Treatment of Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide-1.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

The glucagon superfamily: precursor structure and gene organization

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Distribution and molecular forms of glucagon-like peptide in the dog

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

The proprotein convertases

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Sp3 and Sp4 can repress transcription by competing with Sp1 for the core cis-elements on the human ADH5/FDH minimal promoter

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Impaired intestinal proglucagon processing in mice lacking prohormone convertase 1.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of the prohormone convertase PC3 in the processing of proglucagon to glucagon-like peptide 1.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Proglucagon processing profile in canine L cells expressing endogenous prohormone convertase 1/3 and prohormone convertase 2

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Amidated and non-amidated glucagon-like peptide-1 (GLP-1): non-pancreatic effects (cephalic phase acid secretion) and stability in plasma in humans

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Localization of amidating enzymes (PAM) in rat gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Biological actions and therapeutic potential of the glucagon-like peptides

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Gut peptides and type 2 diabetes mellitus treatment

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced GLP-1 and insulin responses and glucose intolerance after gastric glucose in GRP receptor-deleted mice

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Regulation of Intestinal Proglucagon- Derived Peptide Secretion by Intestinal Regulatory Peptides*

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Synthesis and secretion of glucagon-like peptide-1 by fetal rat intestinal cells in culture

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Regulation of glucagon-like peptide-1 secretion from rat ileum by neurotransmitters and peptides

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Gastrin-releasing peptide is a novel mediator of proximal nutrient-induced proglucagon-derived peptide secretion from the distal gut

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Muscarinic receptors control postprandial release of glucagon-like peptide-1: in vivo and in vitro studies in rats

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

The multifunctional or moonlighting protein CD26/DPPIV.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Structural requirements for catalysis, expression, and dimerization in the CD26/DPIV gene family

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Human serum dipeptidyl peptidase IV (DPPIV) and its unique properties

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Endoproteolysis of glucagon-like peptide (GLP)-1 (7-36) amide by ectopeptidases in RINm5F cells

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

The Inhibitory Effect of Glucagon-Like Peptide-1 (7-36)amide on Antral Motility is Antagonized by Its N-Terminally Truncated Primary Metabolite GLP-1 (9-36)amide

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of truncated glucagon-like peptide-1 on pancreatic hormone release in normal conscious dogs.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

In vivo dynamic distribution of 131I-glucagon-like peptide-1 (7-36) amide in the rat studied by gamma camera.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of half-disappearance times, distribution volumes and metabolic clearance rates of exogenous glucagon-like peptide 1 and glucagon in rats

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Glycation of glucagon-like peptide-1(7-36)amide: characterization and impaired action on rat insulin secreting cells.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Structure-function analysis of a series of glucagon-like peptide-1 analogs.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

NMR studies of the aggregation of glucagon-like peptide-1: formation of a symmetric helical dimer

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide-1 7-36 amide and peptide YY have additive inhibitory effect on gastric acid secretion in man

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Peptide YY, glucagon-like peptide-1, and neurotensin responses to luminal factors in the isolated vascularly perfused rat ileum

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of GLP-1 and 2,5-anhydro-D-mannitol on insulin secretion and plasma glucose in mice

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of leptin in the regulation of glucagon-like peptide-1 secretion

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

The genomic organization of the human GLP-1 receptor gene

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Five out of six tryptophan residues in the N-terminal extracellular domain of the rat GLP-1 receptor are essential for its ability to bind GLP-1.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutations to the third cytoplasmic domain of the glucagon-like peptide 1 (GLP-1) receptor can functionally uncouple GLP-1-stimulated insulin secretion in HIT-T15 cells

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

The third cytoplasmic domain of the GLP-1[7-36 amide] receptor is required for coupling to the adenylyl cyclase system

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Structure of a G-protein-coupling domain of a muscarinic receptor predicted by random saturation mutagenesis

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Different domains in the third intracellular loop of the GLP-1 receptor are responsible for Galpha(s) and Galpha(i)/Galpha(o) activation.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

The positive charge at Lys-288 of the glucagon-like peptide-1 (GLP-1) receptor is important for binding the N-terminus of peptide agonists.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

The Structure-Function Relationship of GLP-1 Related Peptides in the Endocrine Function of the Canine Pancreas

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide-1(7-36)amide: characterization of the domain responsible for binding to its receptor on rat insulinoma RINm5F cells

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Structure-activity relationships of glucagon-like peptide-1(7-36)amide: insulinotropic activities in perfused rat pancreases, and receptor binding and cyclic AMP production in RINm5F cells

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of the effects of various C-terminal and N-terminal fragment peptides of glucagon-like peptide-1 on insulin and glucagon release from the isolated perfused rat pancreas.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of various N-terminal fragments of glucagon-like peptide-1(7-36) on food intake in the neonatal chick.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Bioactive peptides from lizard venoms

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Exendin-4 and glucagon-like-peptide-1: NMR structural comparisons in the solution and micelle-associated states

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

The positive charge of the imidazole side chain of histidine7 is crucial for GLP-1 action

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

GLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

A radioimmunoassay for LY315902, an analog of glucagon-like insulinotropic peptide, and its application in the study of canine pharmacokinetics

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

A synthetic glucagon-like peptide-1 analog with improved plasma stability

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

[Ser2]- and [SerP2] incretin analogs: comparison of dipeptidyl peptidase IV resistance and biological activities in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39).

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Diprotins A and B, inhibitors of dipeptidyl aminopeptidase IV, produced by bacteria

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

K579, a slow-binding inhibitor of dipeptidyl peptidase IV, is a long-acting hypoglycemic agent

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Separation of L-Pro-DL-boroPro into its component diastereomers and kinetic analysis of their inhibition of dipeptidyl peptidase IV. A new method for the analysis of slow, tight-binding inhibition

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Peptidyl ammonium methyl ketones as substrate analog inhibitors of proline-specific peptidases.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonpeptide small-molecular inhibitors of dipeptidyl peptidase IV: N-phenylphthalimide analogs

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Dipeptide phosphonates as inhibitors of dipeptidyl peptidase IV

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

A potent dipeptide inhibitor of dipeptidyl peptidase IV

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-arthritic effects of the novel dipeptidyl peptidase IV inhibitors TMC-2A and TSL-225.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Involvement of dipeptidyl peptidase IV in an in vivo immune response

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of deoxycoformycin and Val-boroPro on the associated catalytic activities of lymphocyte CD26 and ecto-adenosine deaminase

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

CD26 expression and enzymatic activity in recipients of kidney allografts

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Dipeptidyl peptidase IV (DP IV/CD26) mRNA expression in PWM-stimulated T-cells is suppressed by specific DP IV inhibition, an effect mediated by TGF-beta(1)

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short- or long-term administration

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.553

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36106470&oldid=1955574581"